Microsoft publishes case study, Invigor shines

|

Published 28-JUN-2018 11:53 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Leading data and analytics solutions company, Invigor Group (ASX:IVO), yesterday revealed that its SpotLite and Shopper Insights products have been featured in a joint case study published by Microsoft.

IVO penned a strategic memorandum of understanding (MoU) with Microsoft last year. The release of this case study further exemplifies the collaborative nature of this relationship.

Published on the Microsoft News Centre, the study examines how IVO’s products, which are hosted on Microsoft Azure cloud, help retailers become more data-driven by understanding the market and their customers, in turn making better business decisions that ultimate improve sales volume, value and margin.

The study explains the way IVO’s competitive pricing and promotional intelligence product, SpotLite, has driven the success of Brisbane-based retailer, Aussie Hi Fi, one of Australia’s first audio-visual specialists, through real-time competitor price monitoring and price optimisation.

It also looks at the benefits of IVO’s decision to move SpotLite and Shopper Insights — which provides customer segmentation and segment-based recommendations — onto the Microsoft Azure cloud, with the aim of making the most of the latest machine learning technologies and artificial intelligence capabilities.

IVO CEO, Gary Cohen, said that the case study provides ample validation of the Invigor product suite.

“Furthermore, it reaffirms the tightening business relationship we are building with Microsoft,” Cohen added. “As previously noted, our partnership with Microsoft helped facilitate the introduction between Invigor and Neal Analytics, and we look forward to updating shareholders on further outcomes stemming from this partnership in due course.”

It should be noted, however, that IVO is an early stage tech company and success is no guarantee. Investors should seek professional financial advice before making an investment.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X